Exchange Announcement • 12 Oct 2026 08:00
Announcement on Obtaining the Approval Notice for Marketing Application of the Chemical API Vortioxetine Hydrobromide by the Controlled Subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd.
Exchange Announcement • 12 Oct 2026 08:00
Announcement on Obtaining U.S. FDA Clinical Trial Approval for DC7001A Capsules by Wholly-owned Subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.
Exchange Announcement • 29 Sep 2026 08:00
Announcement on Obtaining the Approval Notice for Marketing Application of the Chemical API Brexpiprazole by the Controlled Subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd.
Exchange Announcement • 28 Sep 2026 08:00
Announcement on Progress in Major Asset Restructuring
Exchange Announcement • 28 Sep 2026 08:00